Vokes E E, Gregor A, Turrisi A T
Department of Medicine, University of Chicago Medical Center, and the Cancer Research Center, IL 60637-1470, USA.
Semin Oncol. 1998 Aug;25(4 Suppl 9):66-9.
Patients with stage III non-small cell lung cancer (NSCLC) frequently progress either within the irradiated field or systemically, due to uncontrolled microscopic dissemination present before the time of initial diagnosis. The use of combined modality therapy has led to improved survival rates in recent years. In particular, the use of cisplatin and vinblastine as induction chemotherapy is supported by two large randomized clinical trials. Nevertheless, the large majority of patients still die of progressive disease, thus providing a rationale for the integration of new active agents into the overall treatment plan of these patients. Gemcitabine has demonstrated significant single-agent activity in NSCLC. In addition, preclinical and early clinical data indicate that it is a powerful radiation enhancer. Clinical trials investigating this drug with concurrent radiation therapy in NSCLC are reviewed.
III期非小细胞肺癌（NSCLC）患者常因初始诊断前存在的未控微小播散而在放疗野内或全身出现病情进展。近年来，综合治疗模式的应用提高了生存率。特别是，两项大型随机临床试验支持使用顺铂和长春碱作为诱导化疗。然而，绝大多数患者仍死于疾病进展，因此有理由将新的活性药物纳入这些患者的整体治疗方案。吉西他滨已在NSCLC中显示出显著的单药活性。此外，临床前和早期临床数据表明它是一种强效的放疗增敏剂。本文综述了在NSCLC中对该药物与同步放疗进行研究的临床试验。
